|
Feb 13
|
US pharma giant Merck backs healthcare marketplace HD in Southeast Asia
|
|
Feb 12
|
Why Merck & Co., Inc. (MRK) is Declining
|
|
Feb 11
|
Jim Cramer on Merck & Co., Inc. (MRK): ‘Drug Stocks Are Really Getting Hurt’
|
|
Feb 11
|
Health Canada Approves Merck's KEYTRUDA® (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant trea...
|
|
Feb 11
|
In the crowded cardio space, it’s David vs. Goliath for small biotechs
|
|
Feb 10
|
Merck (MRK) Downgraded by TD Cowen Over Keytruda, Gardasil Concerns
|
|
Feb 10
|
TD Cowen cuts Merck stock to hold on uncertainty around Keytruda, Gardasil
|
|
Feb 10
|
Douglas Baker Bought 1,500% More Shares In Merck
|
|
Feb 9
|
Merck & Co. (MRK): ‘Forget It… It’s China,’ Jim Cramer on Vaccine Rollout Woes
|
|
Feb 8
|
Is Merck & Co., Inc. (MRK) the Best Dividend Stock According to Wall Street Analysts?
|
|
Feb 7
|
Merck Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 6
|
Earnings Update: Merck & Co., Inc. (NYSE:MRK) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
|
|
Feb 6
|
Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
|
|
Feb 6
|
With uncertainty roiling Big Pharma, execs are placing lower-risk bets
|
|
Feb 5
|
Is Merck & Co. (MRK) the Best Dividend Stock to Buy and Hold?
|
|
Feb 5
|
Analysts Defend Merck Amid Investor Concerns Over Weak Guidance
|
|
Feb 5
|
Evaxion Biotech price target lowered to $6 from $35 at Lake Street
|
|
Feb 5
|
Why Merck & Co. Inc. (MRK) Went Down on Tuesday
|
|
Feb 5
|
Merck Is Suffering From a Classic Pharma Problem
|
|
Feb 5
|
Big Pharma is staying quiet on Trump's China tariffs
|